Related Experiment Video
Updated: May 8, 2026
10:40
Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
Published on: August 4, 2012
[Acetaminophen and the liver: damage at therapeutic dose levels?]
1Pharmakologe und Toxikologe, RWTH Aachen. karluwe.petersen@post.rwth-aachen.de
MMW Fortschritte Der Medizin
|August 23, 2013
Summary
Paracetamol (acetaminophen) is unlikely to cause liver damage at recommended therapeutic doses. Transient liver enzyme elevations do not confirm liver injury unless accompanied by other clinical signs of liver dysfunction.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Paracetamol (acetaminophen) is a widely used analgesic and antipyretic.
- Concerns exist regarding its potential for liver toxicity, even at therapeutic doses.
- Retrospective studies suggest a risk, but controlled prospective data are limited.
Purpose of the Study:
- To evaluate the evidence for liver injury associated with therapeutic paracetamol use.
- To clarify the significance of transient transaminase elevations.
- To identify established risk factors for hepatotoxicity at regular dose levels.
Main Methods:
- Review of retrospective and prospective studies on paracetamol use.
- Analysis of criteria for diagnosing paracetamol-induced liver injury.
- Assessment of potential risk factors like malnutrition, ethanol, and drug interactions.
Main Results:
- Controlled prospective studies do not support liver intoxication at therapeutic paracetamol doses (up to 4g/day).
- Retrospective reports may misjudge intentional or suicidal overdoses.
- Malnutrition, ethanol, and enzyme-inducing drugs are not established risk factors at therapeutic levels.
- Transient transaminase increases alone, without symptoms or other lab changes (bilirubin, INR), do not indicate liver damage.
Conclusions:
- There is insufficient evidence of liver injury from paracetamol at regular therapeutic doses.
- Dose adjustments are recommended for patients with pre-existing liver disease during long-term use.
- Clinical context and comprehensive liver function tests are crucial for diagnosing paracetamol hepatotoxicity.
Related Concept Videos
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...